Trial Profile
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) [EXTENSION OF 700243221]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2014
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms BUILD OL
- Sponsors Actelion Pharmaceuticals
- 15 Apr 2014 New trial record
- 09 Mar 2012
- 11 Jun 2010